At week @ , reductions in HbA@c ( mean baseline @-@ @ % -LSB- @-@ @ mmol/mol -RSB- ) with empagliflozin/linagliptin were superior to those with empagliflozin or linagliptin alone as add-on to metformin ; adjusted mean ( SE ) changes from baseline were -@ % ( @ ) ( -@ mmol/mol -LSB- @ -RSB- ) with empagliflozin @ mg/linagliptin @ mg , -@ % ( @ ) ( -@ mmol/mol -LSB- @ -RSB- ) with empagliflozin @ mg/linagliptin @ mg , -@ % ( @ ) ( -@ mmol/mol -LSB- @ -RSB- ) with empagliflozin @ mg , -@ % ( @ ) ( -@ mmol/mol -LSB- @ -RSB- ) with empagliflozin @ mg , and -@ % ( @ ) ( -@ mmol/mol -LSB- @ -RSB- ) with linagliptin @ mg ( P < @ for all comparisons ) .